Moderna Inc. ($MRNA) Stock Forecast: Down 5.1% Today

What is Moderna Inc.?

Moderna (MRNA) is a biotechnology company acclaimed for its mRNA technology utilized in creating vaccines, such as the COVID-19 vaccine. The general market sentiment towards Moderna has been pessimistic today.

Why is Moderna Inc. going down?

MRNA stock is down 5.1% on Jul 1, 2024 17:15

• A Moderna director selling over $1.9 million in company stock possibly indicated a lack of faith in the company's future, sparking investor worries and a downward trend in the stock.
• The partnership between Carisma Therapeutics and Moderna on a novel development candidate may have raised uncertainties about Moderna's internal pipeline and potential competition, influencing the stock negatively.
• Despite positive developments like EMA panel support for Moderna's older adult RSV vaccine, the prevailing market sentiment could have been impacted more by the insider selling and competitive landscape concerns, contributing to the stock's bearish performance today.

MRNA Price Chart

MRNA News

Trump Media & Technology And Grindr Were Among The 10 Biggest Mid-Cap Stock Gainers Last Week ( June 23 - June 29 ) : Are These In Your Portfolio? - Grindr ( NYSE:GRND ) , Trump Media & Technology ( NASDAQ:DJTWW )

These mid-cap stocks were the best performers in the last week. Are they in your portfolio? Moderna And Walgreens Boots Alliance Were Among The 10 Biggest Large Cap Losers Last Week ( June 23 - June 29 ) : Are These In Your Portfolio?

https://www.benzinga.com/news/mid-cap/24/06/39565880/trump-media-technology-and-grindr-were-among-the-10-biggest-mid-cap-stock-gainers-last-week-june-23

Moderna director Afeyan sells over $1.9 million in company stock

https://www.investing.com/news/company-news/moderna-director-afeyan-sells-over-19-million-in-company-stock-93CH-3502221

https://www.investing.com/news/company-news/moderna-director-afeyan-sells-over-19-million-in-company-stock-93CH-3502221

Alexandria Real Estate Equities, Inc. Releases 2023 Corporate Responsibility Report Highlighting Its Longstanding Leadership at the Vanguard and Heart of the Life Science Industry

Alexandria announces that a recently completed large-scale solar farm is now supplying renewable power to meet 100% of its Greater Boston region''s electricity load through a long-term power purchase agreement Alexandria joined Moderna and the Massachusetts governor on June 26 to celebrate…

https://www.prnewswire.com/news-releases/alexandria-real-estate-equities-inc-releases-2023-corporate-responsibility-report-highlighting-its-longstanding-leadership-at-the-vanguard-and-heart-of-the-life-science-industry-302185951.html

Why Are Carisma Therapeutics Shares Surging Friday?

Carisma Therapeutics Inc. (NASDAQ: CARM ) shares are trading higher on Friday following the company’s announcement of a significant development in its collaboration with Moderna . What To Know: Carisma has nominated its first in vivo CAR-M development candidate targeting Glypican-3 (GPC3) for the treatment of solid tumors, including hepatocellular carcinoma (HCC). This milestone has triggered a $2 million payment to Carisma from Moderna. The development candidate leverages Carisma’s expertise in engineering chimeric antigen receptor … Full story available on Benzinga.com

https://www.benzinga.com/news/24/06/39555637/why-are-carisma-therapeutics-shares-surging-friday

EMA panel backs Moderna''s older adult RSV vaccine

https://www.investing.com/news/company-news/ema-panel-backs-modernas-older-adult-rsv-vaccine-93CH-3501746

https://www.investing.com/news/company-news/ema-panel-backs-modernas-older-adult-rsv-vaccine-93CH-3501746

Trending Today

Solana ($SOL) Crypto Forecast: Up 5.1% Today

Wormhole ($W) Crypto Forecast: Up 6.5% Today

Monero ($XMR) Crypto Forecast: Up 5.6% Today

Shiba Inu ($SHIB) Crypto Forecast: Up 11.3% Today

Polkadot ($DOT) Crypto Forecast: Up 6.3% Today

Pepe ($PEPE) Crypto Forecast: Up 8.8% Today

XRP ($XRP) Crypto Forecast: Up 5.3% Today

Avalanche ($AVAX) Crypto Forecast: Up 5.1% Today

dogwifhat ($WIF) Crypto Forecast: Up 13.4% Today

Toncoin ($TON) Crypto Forecast: Up 6.8% Today

Moderna Inc. Price History

27.05.2024 - MRNA Stock was down 5.3%

• Moderna's stock plummeted by 11% following reports of the company's RSV vaccine efficacy lagging behind competitors, such as Pfizer.
• The decline was exacerbated by recent updates on RSV vaccine restrictions from the CDC, impacting not only Moderna but also other vaccine manufacturers like GSK.
• Investors reacted strongly to the developments, indicating concerns about Moderna's competitive position in the vaccine market and potential implications for its future revenue.
• The upcoming meeting of the CDC's Advisory Committee on Immunization Practice to discuss vaccine recommendations added further uncertainty, contributing to the negative sentiment surrounding Moderna's stock.

27.05.2024 - MRNA Stock was down 6.8%

• Moderna's stock (MRNA) experienced a significant bearish movement, dropping over 11%.
• The decline in Moderna's shares can be attributed to the lagging efficacy of its RSV vaccine compared to competitors like GSK and Pfizer, with its RSV shot being reported as 50% effective after 18 months in contrast to GSK's Arexvy at 78% effectiveness.
• Investors may be concerned about Moderna's competitive position in the vaccine market, especially with the upcoming meeting of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practice to discuss recommendations for RSV, influenza, and COVID-19 vaccines.
• The market reaction suggests that investors are closely monitoring Moderna's vaccine developments and efficacy data, leading to a bearish sentiment as the company faces challenges in maintaining a competitive edge in the vaccine industry.

26.05.2024 - MRNA Stock was down 10.3%

• Moderna stock faced a bearish trend following development related to the CDC's Advisory Committee meeting discussing vaccine recommendations for RSV, influenza, and COVID-19.
• The dip in Moderna's stock price is linked to the recently released efficacy data of its RSV vaccine, which stood at 50%, lower than competitors like GSK and Pfizer.
• Investors' negative reaction to the news suggests disappointment with Moderna's performance in the RSV vaccine segment, causing a decline in the stock price.

26.05.2024 - MRNA Stock was down 6.5%

• Moderna's stock saw a bearish trend possibly due to concerns raised by a US soldier attributing a debilitating heart condition to the Moderna COVID vaccine, leading to potential vaccine safety worries among investors.
• Competition in the RSV vaccine market could have impacted Moderna's stock negatively, as its RSV shot was reported to be 50% effective after 18 months, compared to GSK and Pfizer's vaccines which showed higher effectiveness rates over a longer period.
• Despite Moderna surpassing market returns recently, the news of lower efficacy of its RSV shot and vaccine safety concerns might have overshadowed this positive development, contributing to the bearish movement.

26.05.2024 - MRNA Stock was down 5.8%

• Moderna's stock exhibited a downward trend, potentially linked to a US soldier's report of a severe heart condition post-receiving the Moderna COVID vaccine. This development raised safety concerns and cast doubts on the company's reputation.
• The announcement of a partnership between Eli Lilly and Microsoft-supported OpenAI may have shifted investor focus towards potential healthcare sector innovations, leading to decreased attention on Moderna.
• Novavax submitting an application for an updated COVID-19 vaccine aimed at a specific variant could have influenced investor sentiment, prompting a sell-off of Moderna shares.
• The utilization of ChatGPT by Moderna employees for various purposes, although intriguing, is unlikely to have directly impacted the stock's recent decline.

14.05.2024 - MRNA Stock was down 5.4%

• Despite positive updates on its COVID-Flu Combo Jab achieving late-stage study milestones, Moderna's stock (MRNA) encountered a bearish trend.
• The market's response to Moderna submitting an updated COVID-19 vaccine for FDA review seemed negative, possibly due to uncertainties surrounding the approval process.
• Amidst a general market upsurge and growing optimism, investor attention appeared to drift away from Moderna's stock, influencing the bearish movement.
• Mixed investor sentiments arose from the FDA's vigilant approach towards new variants and the approval of updated vaccines, ultimately impacting Moderna's stock performance adversely.

06.05.2024 - MRNA Stock was up 5.4%

• The inclusion of Moderna in the U.S. FDA's START Pilot Program for its investigational therapeutic signifies a promising opportunity for future growth and market expansion.
• FDA's approval of Moderna's mRESVIA for mRNA vaccines across various indications is a contributing factor to the market's bullish trend, demonstrating the company's success in regulatory approvals.
• Positive market sentiment within the biotech industry, as evidenced by the recovery and growth potential in pharmaceutical stocks, may be influencing investor confidence and boosting Moderna's stock price.
• Global concerns regarding avian influenza and the recent WHO confirmation of a bird flu fatality in Mexico could indirectly benefit Moderna's stock, as the emphasis on health and vaccine development increases, potentially favoring companies like Moderna involved in this sector.

05.05.2024 - MRNA Stock was up 5.8%

• Moderna experienced a strong bullish movement in its stock today, potentially influenced by various positive factors:
• Reaffirmation of commitment to supply updated COVID-19 vaccines for the upcoming fall immunization campaign, signaling ongoing advancements in combating the pandemic.
• FDA approval of Moderna's mRNA-based respiratory syncytial virus (RSV) vaccine for individuals aged 60 and above, broadening the company's vaccine offerings and market opportunities.
• Despite the CFO's sale of some shares, the overall positivity stemming from encouraging trial outcomes in cancer therapies and diagnostics, along with personalized mRNA cancer vaccines, might have bolstered investor confidence and the bullish market trend for Moderna.

05.05.2024 - MRNA Stock was up 5.8%

• The recent stock sell-off by Moderna's CFO initially raised concerns, but the market's bullish movement suggests that investors are more focused on the company's performance and potential.
• The FDA approval of Moderna's mRNA-based RSV vaccine for older adults may have contributed to the optimistic market sentiment.
• Positive trial results in cancer treatment and diagnostics by Moderna and other companies like Merck likely increased investor confidence in the future of mRNA-based therapies.
• Today's bullish movement in Moderna's stock was likely influenced by a combination of positive FDA approvals and promising trial results in the healthcare sector.

03.05.2024 - MRNA Stock was up 5.8%

• Moderna's stock experienced a bullish trend following multiple positive developments regarding its vaccine technologies.
• FDA approval of Moderna's RSV vaccine for older adults indicates the company's expansion beyond Covid-19 vaccines, boosting investor confidence.
• The successful results of Moderna's cancer vaccine in improving patient survival further contributed to the positive sentiment around the stock.
• The continuous innovation and regulatory approvals position Moderna as a frontrunner in the biotech industry, driving the bullish movement in its stock price.

31.04.2024 - MRNA Stock was down 6.1%

• The FDA approval of Moderna's mRNA RSV vaccine for older adults was a positive development for the company.
• Surprisingly, the approval of a new vaccine did not have the expected positive impact on the stock, which could be due to market expectations being already priced in.
• Investors might be concerned about the company's revenue diversification strategy, as the approval comes at a time when demand for its COVID-19 vaccine is declining.
• The market might be reacting to the competitive landscape as Moderna faces challenges in differentiating its RSV vaccine in a crowded market of mRNA vaccines.

31.04.2024 - MRNA Stock was down 5.1%

• The FDA's approval of Moderna's RSV vaccine for older adults was a significant milestone, demonstrating the company's diversification beyond COVID-19 vaccines.
• Interestingly, the market responded negatively to this update, potentially reflecting the already high investor expectations embedded in the stock.
• Concerns may arise among investors regarding the competitive environment, with Moderna's RSV vaccine posing a possible challenge to industry giants like Pfizer and GSK.
• Market sentiment could be influenced by profit-taking actions subsequent to the recent positive developments, contributing to the decline in Moderna's stock value.